SR-4370 | CAS#1816294-67-3 | HDAC inhibitor

MedKoo Cat#: 206964 | Name: SR-4370

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SR-4370 is an HDAC inhibitor. SR-4370 exhibited IC50 values of 0.5 μM, 0.1 μM and 0.06 μM towards HDAC1, HDAC2 and HDAC3, resp. SR-4370 is reported in WO 2015153516. SR-4370 showed comparable performances to other already known LRAs, did not activate CD4+ T cells, and did not cause changes in the composition of peripheral blood mononuclear cells (PBMCs), as shown by flow cytometry analyses.

Chemical Structure

SR-4370

CAS#1816294-67-3

Theoretical Analysis

MedKoo Cat#: 206964

Name: SR-4370

CAS#: 1816294-67-3

Chemical Formula: C17H18F2N2O

Exact Mass: 304.1387

Molecular Weight: 304.34

Elemental Analysis: C, 67.09; H, 5.96; F, 12.48; N, 9.20; O, 5.26

Price and Availability

Size	Price	Availability
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,250.00	Ready to ship
500mg	USD 2,650.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SR-4370; SR 4370; SR4370;

IUPAC/Chemical Name

N'-butyl-2',3'-difluoro-[1,1'-biphenyl]-4-carbohydrazide

InChi Key

OSQKWTZHYXRTBG-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H18F2N2O/c1-2-3-11-20-21-17(22)13-9-7-12(8-10-13)14-5-4-6-15(18)16(14)19/h4-10,20H,2-3,11H2,1H3,(H,21,22)

SMILES Code

O=C(C1=CC=C(C2=CC=CC(F)=C2F)C=C1)NNCCCC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO and ethanol

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#C23R01B21

QC Data

View QC data: current batch, Lot#C23R01B21

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

SR-4370 is an inhibitor of HDAC, with IC50s of 0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC6, respectively.

In vitro activity:

SR-4370 may has therapeutic potential for the reversal of latency in HIV-1-infected individuals. SR-4370 showed comparable performances to other already known latency-reversing agents, did not activate CD4+ T cells, and did not cause changes in the composition of peripheral blood mononuclear cells (PBMCs), as shown by flow cytometry analyses. Reference: Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01815-20. https://pubmed.ncbi.nlm.nih.gov/33139279/

In vivo activity:

To be determined

	Solvent	mg/mL	mM
Solubility
	DMSO	105.5	346.65
	Ethanol	61.0	200.43

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 304.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Zutz A, Chen L, Sippl F, Humpe A, Schölz C. Epigenetic Compound Screening Uncovers Small Molecules for Reactivation of Latent HIV-1. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01815-20. doi: 10.1128/AAC.01815-20. PMID: 33139279; PMCID: PMC7927817.

In vitro protocol:

In vivo protocol:

To be determined

Zutz A, Chen L, Sippl F, Humpe A, Schölz C. Epigenetic Compound Screening Uncovers Small Molecules for Reactivation of Latent HIV-1. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01815-20. doi: 10.1128/AAC.01815-20. PMID: 33139279; PMCID: PMC7927817.